Page 98 - 《中国药房》2025年20期

参考文献 ment and first validation of the COPD assessment test[J].
[ 1 ] DENTON E，O’HEHIR R E，HEW M. The changing Eur Respir J，2009，34（3）：648-654.
global prevalence of asthma and atopic dermatitis[J]. Al‐ [15] MARKS G B，DUNN S M，WOOLCOCK A J. An evalua‐
lergy，2023，78（8）：2079-2080. tion of an asthma quality of life questionnaire as a mea‐
[ 2 ] 王凤燕，梁振宇，何文强，等. 慢性阻塞性肺疾病年度进 sure of change in adults with asthma[J]. J Clin Epidemiol，
展2024[J]. 中华结核和呼吸杂志，2025，48（1）：60-65. 1993，46（10）：1103-1111.
[ 3 ] LEUNG C，SIN D D. Asthma-COPD overlap：what are [16] JONES P W，QUIRK F H，BAVEYSTOCK C M. The St
the important questions? [J]. Chest，2022，161（2）： George’s respiratory questionnaire[J]. Respir Med，1991，
330-344. 85：25-31.
[ 4 ] MORISSETTE M，GODBOUT K，CÔTÉ A，et al. Asthma [17] LINS L，CARVALHO F M. SF-36 total score as a single
COPD overlap：insights into cellular and molecular measure of health-related quality of life：scoping review
[J]. SAGE Open Med，2016，4：2050312116671725.
mechanisms[J]. Mol Aspects Med，2022，85：101021.
[ 5 ] PETOUSI N，PAVORD I D，KENT B D. Type-2 inflam‐ [18] CASTRO M，CORREN J，PAVORD I D，et al. Dupilumab
efficacy and safety in moderate-to-severe uncontrolled
mation：a key treatable trait associated with lung function
asthma[J]. N Engl J Med，2018，378（26）：2486-2496.
decline in chronic airways disease[J]. Thorax，2024，79
[19] HUDLER A，HOLGUIN F，SHARMA S. Pathophysio-
（4）：291-292.
logy of asthma-chronic obstructive pulmonary disease
[ 6 ] TU X F，DONOVAN C，KIM R Y，et al. Asthma-COPD
overlap[J]. Immunol Allergy Clin North Am，2022，42
overlap：current understanding and the utility of experi‐
（3）：521-532.
mental models[J]. Eur Respir Rev，2021，30（159）：
[20] LE FLOC’H A，ALLINNE J，NAGASHIMA K，et al.
190185.
Dual blockade of IL-4 and IL-13 with dupilumab，an IL-
[ 7 ] BUSSE W W，KRAFT M，RABE K F，et al. Under-
4Rα antibody，is required to broadly inhibit type 2 inflam‐
standing the key issues in the treatment of uncontrolled
mation[J]. Allergy，2020，75（5）：1188-1204.
persistent asthma with type 2 inflammation[J]. Eur Respir
[21] LEUZZI G，GALEONE C，TAVERNA F，et al. C-reactive
J，2021，58（2）：2003393.
protein level predicts mortality in COPD：a systematic
[ 8 ] MATSUNAGA K，KATOH N，FUJIEDA S，et al. Dupi-
review and meta-analysis[J]. Eur Respir Rev，2017，26
lumab：basic aspects and applications to allergic diseases
（143）：160070.
[J]. Allergol Int，2020，69（2）：187-196.
[22] SHIM J S，KIM H，KWON J W，et al. A comparison of
[ 9 ] NUMATA T，ARAYA J，MIYAGAWA H，et al. Real-
treatment response to biologics in asthma-COPD overlap
world effectiveness of dupilumab for patients with severe
and pure asthma：findings from the PRISM study[J].
asthma：a retrospective study[J]. J Asthma Allergy，2022，
World Allergy Organ J，2023，16（12）：100848.
15：395-405.
[23] LI H W，ZHANG Q，WANG J R，et al. Variability of type
[10] REDDEL H K，BACHARIER L B，BATEMAN E D，et al.
2 inflammatory markers guiding biologic therapy of se‐
Global initiative for asthma strategy 2021：executive sum‐
vere asthma：a 5-year retrospective study from a single ter‐
mary and rationale for key changes[J]. Am J Respir Crit
tiary hospital[J]. World Allergy Organ J，2021，14（9）：
Care Med，2022，205（1）：17-35. 100547.
[11] AGUSTÍ A，CELLI B R，CRINER G J，et al. Global initia‐
[24] 胡建，许丽，王雪艳，等. 度普利尤单抗对儿童支气管哮
tive for chronic obstructive lung disease 2023 report：gold 喘及其2型炎症共病的疗效分析[J]. 中华实用儿科临床
executive summary[J]. Am J Respir Crit Care Med，2023， 杂志，2023，38（7）：521-527.
207（7）：819-837. [25] BOURDIN A，PAPI A A，CORREN J，et al. Dupilumab is
[12] SIN D D，MIRAVITLLES M，MANNINO D M，et al. effective in type 2-high asthma patients receiving high-
What is asthma-COPD overlap syndrome：towards a con‐ dose inhaled corticosteroids at baseline[J]. Allergy，2021，
sensus definition from a round table discussion? [J]. Eur 76（1）：269-280.
Respir J，2016，48（3）：664-673. [26] KYCHYGINA A，CASSAGNE M，TAUBER M，et al.
[13] SCHATZ M，SORKNESS C A，LI J T，et al. Asthma con‐ Dupilumab-associated adverse events during treatment of
trol test：reliability，validity，and responsiveness in pa‐ allergic diseases[J]. Clin Rev Allergy Immunol，2022，62
tients not previously followed by asthma specialists[J]. J （3）：519-533.
Allergy Clin Immunol，2006，117（3）：549-556. （收稿日期：2025-04-10 修回日期：2025-08-28）
[14] JONES P W，HARDING G，BERRY P，et al. Develop‐ （编辑：张元媛）

· 2576 · China Pharmacy 2025 Vol. 36 No. 20 中国药房 2025年第36卷第20期